Skip to main content

Table 1 Baseline characteristics of patients

From: Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure

Clinical characteristics 
 Age, years68 (60–73)
 Gender (female), n (%)21 (38)
 Body mass index, kg/m225.9 ± 5.1
 Systolic blood pressure, mmHg130 ± 16
 BNP, pg/mL27.9 (9.0–58.2)
 eGFR, mL/min/1.73 m270.6 ± 17.0
 HbA1c, %7.2 ± 0.8
HF classification, n (%)
 HFpEF37 (69)
 HFrEF7 (13)
 HFmrEF9 (17)
Comorbidities, n (%)
 Hypertension43 (81)
 Dyslipidemia42 (79)
 Cardiovascular event12 (21)
Medications, n (%)
 CCB19 (36)
 ACEI/ARB42 (79)
 β-Blocker27 (51)
 Diuretics10 (19)
 Statin37 (70)
Antidiabetic drugs
 DPP-4I40 (75)
 GLP-1 RA1 (2)
 SU11 (21)
 α-GI9 (17)
 Thiazolidinedione11 (21)
 Metformin14 (26)
Echocardiographic parameters
 LV end-diastolic volume, mL74.2 (55.1–104.1)
 LV end-systolic volume, mL24.7 (17.0–54.5)
 LVEF, %62.3 (49.3–68.3)
 LVMI, g/m275.0 (61.7–92.0)
 LAVI, mL/m231 (23–45)
 E/e′9.3 (7.7–11.8)
  1. Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
  2. DM diabetes mellitus, BNP plasma brain natriuretic peptide, HF heart failure with preserved ejection fracti, HFrEF heart failure with reduced ejection fracti, HFm heart failure with mid-range ejection fraction, CCB calcium channel block, ACEI angiotensin-converting enzyme inhibit, ARB angiotensin II receptor block, DPP-4I Dipeptidyl Peptidase-4 inhibit, GLP-1 RA glucagon-like peptide-1 receptors agonists, SU Sulfonylureas, α-GI α-glucosidase inhibitors, LVEF left ventricular ejection fraction, LVMI left ventricular mass index, LAVI left atrial volume index, E peak early diastolic mitral flow velocity, e′ Spectral pulsed-wave Doppler-derived early diastolic velocity from the septal mitral annulus